Large-scale metabolic biomarker profiling for researchers
Capture the body’s core metabolic functions from just €24 per sample.
Nightingale Health’s metabolomic research service enables reproducible and cost-effective measurement of lipids, inflammation, dietary intake, insulin sensitivity, and much more.
Our biomarkers are associated with diverse aspects of human health, from cardiometabolic disease to kidney and liver function to dementia and mental health. They also reflect the exposome, including smoking, and diet, providing foundational data for every analysis in your study.
If you genotype each sample, you should also have a metabolic snapshot as part of the basic core data. Take your research to the next level with metabolic insights across human health.
Nightingale Health brings metabolomics to the scale of the world’s largest biobanks and cohorts.
Our research service provides the only platform for comprehensive metabolic profiling for whole cohorts. Nightingale Health's technology is the only omics technology that has been measured across all 500,000 participants in the UK Biobank and 200,000 participants in the Estonian Biobank.
We are proud to have partnered with these world-leading medical research studies and that our data are available to qualified researchers to amplify and replicate new research findings and increase impact. You can also explore our atlas of biobank associations in UK Biobank.
"The cost difference between this panel and measuring standard lipids and glucose, when considering all of the additional information provided, for me, makes a clear argument for using Nightingale's platform."
Professor Deborah Lawlor
MRC Integrative Epidemiology Unit
University of Bristol
Nightingale Health’s metabolic biomarker profiles have become a trusted and affordable gold standard for our customers, which has led to millions of samples analyzed to date.
Replace your clinical chemistry measurements with Nightingale Health for about the price of a cholesterol test.
We have clinically validated 39 biomarkers that are reported in the same absolute concentration units and reference ranges as traditional clinical chemistry measurements.
In addition to your research goals, feedback actionable measurements to your research participants, including individual biomarkers and multi-biomarker disease risk predictions.
Metabolic insights: Nightingale's biomarkers in smoking and lung cancer risk
“The results highlight that Nightingale’s biomarkers provide a quantitative proxy for smoking exposure and may be used as a tool for predicting smoking-related disease risk.”
Smoking is well known as a dramatic risk factor for chronic diseases like lung cancer, chronic obstructive pulmonary disease (COPD), and heart disease. It also increases the risk of many other diseases to different degrees and is in general one of the most important covariates in epidemiological analyses.
In our recent blog post, we learned from the UK Biobank data, how our blood biomarkers predict lung cancer compared to pack-years of smoking.
Diabetes UK Professional Conference
17 April – 19 April, London, United Kingdom
ESC Preventive Cardiology Congress
25 April – 27 April, Athens, Greece
See full list of upcoming events
Nightingale Health Research News is a newsletter for scientists sharing insights on the latest publications in the field of metabolic profiling, stories from researchers we work with, and the benefits of using Nightingale Health's technology to fuel research.